Shares of Moderna ($MRNA) closed up nearly 177% at $174.38 on August 19 after the company and Merck ($MRK) announced positive Phase 3 results for their personalized mRNA cancer therapy, pushing Moderna's gain since a previously disclosed March Moderna purchase by President Donald Trump's investment account to more than 225% at the close.
- Trump disclosed a $15,001-$50,000 Moderna purchase dated March 2 and another $1,001-$15,000 purchase dated March 17.
- Quiver highlighted the trades in July, when Moderna was up roughly 46% from the March 2 transaction.
- Moderna subsequently received FDA approval for its mRNA flu vaccine, mFLUSIVA, in August.
- On August 19, Moderna and Merck said the 1,137-patient INTerpath-001 trial met its recurrence-free survival and distant metastasis-free survival endpoints.
- The companies described it as the first positive Phase 3 readout for an mRNA-based cancer therapy.
- Moderna shares surged nearly 177% on August 19 following the announcement.
Relevant Companies
- Moderna ($MRNA) - Co-developer of intismeran and developer of its underlying mRNA platform.
- Merck ($MRK) - Co-developer of intismeran and maker of KEYTRUDA, used in the successful combination.
Editor’s Note: This is a developing story. This article may be updated as more details become available.
